Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28349939 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL31221886 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL7597590 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL30933601 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL6251235 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL128713 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL335062 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL21538667 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL353568 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL29367357 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012127385-A1 | BENZO [B] [1, 4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2012-09-27 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| EP-1148876-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | claimed |
| EP-1148876-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2001-10-31 | — | — | EP | claimed |
| WO-2000045816-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (GB) | 2000-08-10 | — | — | WO | claimed |
| CN-119662740-A | Stable, efficient and environment-friendly silver nanoparticle lactobacillus biosynthesis method and application | 郑州轻工业大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20240350643-A1 | PROTEIN DEGRADATION AGENT | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2024-10-24 | — | — | US | disclosed |
| CN-118724676-A | Entecavir Process for the preparation of intermediates | 南京工业大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-118164913-A | Indenopiperidine derivatives, and preparation method and application thereof | 浙江大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-4361141-A1 | PROTEIN DEGRADATION AGENT | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-117545749-A | Protein degradation agent | 苏州开拓药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-115504963-A | C-Myc protein degradation agent | 苏州开拓药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| US-20060004230-A1 | Process for the preparation of terbinafine and salts thereof | CHEMAGIS LTD. (IL) | 2006-01-05 | — | — | US | disclosed |
| EP-1148876-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1148876-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000045816-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (GB) | 2000-08-10 | — | — | WO | disclosed |
| EP-0907631-A1 | INORGANIC ION RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997041090-A1 | INORGANIC ION RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350643-A1 | PROTEIN DEGRADATION AGENT | MYC, MYCBP, MYCBP2 | GLA 1300/4885ADRA2A 4557/4885ADRA2B 4680/4885 |
| US-20060004230-A1 | Process for the preparation of terbinafine and salts thereof | TPMT, HNMT, DHPS | GLA 3718/4885ADRA2A 3672/4885ADRA2B 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.